


## ZXH-4-130

Cat. No.:	HY-132857
CAS No.:	2711006-66-3
Molecular Formula:	C <sub>46</sub> H <sub>58</sub> N <sub>6</sub> O <sub>9</sub> S
Molecular Weight:	871.05
Target:	PROTACs
Pathway:	PROTAC
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	ZXH-4-130 is a highly potent and selective degrader of CRBN. ZXH-4-130 is a CRBN-VHL compound (hetero-PROTAC) <sup>[1]</sup> .																
<b>IC<sub>50</sub> &amp; Target</b>	VHL																
<b>In Vitro</b>	<p>ZXH-4-130 (100 nM; 2 h pre-treatments; followed by 96-hour treatment with 1 μM of Pomalidomide) prevents Pomalidomide (1 μM) cytotoxicity to a significant extent, ZXH-4-130 has statistically significant amounts of prevention<sup>[1]</sup>.</p> <p>MM1.S cells are pre-treated for 2 h with 50 nM of ZXH-4-130, before exposing them to CC-885, a compound that induces G1 to S phase transition protein 1 (GSPT1) degradation via CRBN E3 ligase recruitment. Pretreatment with 50 nM of ZXH-4-130 rescues GSPT1 degradation<sup>[1]</sup>.</p> <p>ZXH-4-130 (100 nM 2 h pre-treatment; followed by 6 h treatment with THAL-SNS-032) induces nearly complete CRBN degradation, but THAL-SNS-032's activity against CDK9 is only partially prevented<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>MM1.S cells</td> </tr> <tr> <td>Concentration:</td> <td>100 nM</td> </tr> <tr> <td>Incubation Time:</td> <td>2 h pre-treatments; followed by 96-hour treatment with 1 μM of Pomalidomide</td> </tr> <tr> <td>Result:</td> <td>Prevented Pomalidomide cytotoxicity to a significant extent, ZXH-4-130 has statistically significant amounts of prevention.</td> </tr> </table> <p>Western Blot Analysis<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>MM1.S cells</td> </tr> <tr> <td>Concentration:</td> <td>50 nM</td> </tr> <tr> <td>Incubation Time:</td> <td>2 h pretreatment with ZXH-4-130, followed by 4 h treatment with CC-885</td> </tr> <tr> <td>Result:</td> <td>Rescued GSPT1 degradation.</td> </tr> </table>	Cell Line:	MM1.S cells	Concentration:	100 nM	Incubation Time:	2 h pre-treatments; followed by 96-hour treatment with 1 μM of Pomalidomide	Result:	Prevented Pomalidomide cytotoxicity to a significant extent, ZXH-4-130 has statistically significant amounts of prevention.	Cell Line:	MM1.S cells	Concentration:	50 nM	Incubation Time:	2 h pretreatment with ZXH-4-130, followed by 4 h treatment with CC-885	Result:	Rescued GSPT1 degradation.
Cell Line:	MM1.S cells																
Concentration:	100 nM																
Incubation Time:	2 h pre-treatments; followed by 96-hour treatment with 1 μM of Pomalidomide																
Result:	Prevented Pomalidomide cytotoxicity to a significant extent, ZXH-4-130 has statistically significant amounts of prevention.																
Cell Line:	MM1.S cells																
Concentration:	50 nM																
Incubation Time:	2 h pretreatment with ZXH-4-130, followed by 4 h treatment with CC-885																
Result:	Rescued GSPT1 degradation.																

---

## REFERENCES

---

[1]. Chelsea E Powell, et al. Selective degradation-inducing probes for studying cereblon (CRBN) biology. RSC Med Chem. 2021 Jul 6;12(8):1381-1390.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA